1. Red-hot biotechs to take spotlight at ASH virtual meeting — Moderna's 3-month data raise hopes for COVID-19 vaccine durability — BioNTech founder vaults into world's 500 richest — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Abbott reports in-line earnings for Q3; sales miss view

Discussion in 'Abbott' started by anonymous, Oct 16, 2019 at 8:20 AM.

  1. anonymous

    anonymous Guest

    Abbott Laboratories’ third quarter 2019 earnings came in line with the market’s projections, while sales missed the expectations. The pharma company reported adjusted EPS of $0.84 on sales of $8.08 billion. Wall Street had forecasted Abbott to post earnings of $0.84 on sales of $8.11 billion. Abbott stock dipped 2% in the pre-market trading session. Read more